Patents/Inventors

Stuart Milstein

Arlington, MAUS18 patents

20 Patents

US125656532026
ATAXIN3 (ATXN3) Rnai Agent Compositions and Methods of Use Thereof
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US124670512025
Angiopoietin-like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US124602062025
PCSK9 Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US123970132025
Extrahepatic Delivery
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US123850432025
Modified Double-stranded RNA Agents
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US123850442025
Modified Double-stranded RNA Agents
Alnylam Pharmaceuticals, Inc.
0 cites
US123785532025
Modified Double-stranded RNA Agents
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US123592012025
17ß-hydroxysteroid Dehydrogenase Type 13 (HSD17B13) Irna Compositions and Methods of Use Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US122277442025
Compositions and Methods for Inhibiting Expression of Transthyretin
Alnylam Pharmaceuticals, Inc.
0 cites
US121732892024
Hepatitis B Virus (HBV) Dsrna Agent Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US121687672024
Modified Double-stranded RNA Agents
Alnylam Pharmaceuticals, Inc.
0 cites
US120916612024
Organic Compositions to Treat Hsf1-related Diseases
Arrowhead Pharmaceuticals, Inc.
0 cites
US120050742024
Extrahepatic Delivery
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US118667092024
Angiopoietin-like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US118406922023
Angiopoietin-like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US118346622023
Angiopoietin-like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US117252072023
Serpina1 Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US117252092023
TMPRSS6 Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US116494592023
Superoxide Dismutase 1 (SOD1) Irna Compositions and Methods of Use Thereof for Treating or Preventing Superoxide Dismutase 1-(SOD1-) Associated Neurodegenerative Diseases
Alnylam Pharmaceuticals, Inc.
0 cites
US115491092023
Modified Double-stranded RNA Agents
Alnylam Pharmaceuticals, Inc.
0 cites